Frailty and risk of serious infections in patients with rheumatoid arthritis treated with biologic or targeted-synthetic DMARDs.
Namrata SinghLaura S GoldJiha LeeKatherine D WyshamJames S AndrewsUna E MakrisBryant R EnglandMichael D GeorgeJoshua F BakerJeffrey JarvikPatrick J HeagertySiddharth SinghPublished in: Arthritis care & research (2023)
Frailty is an important predictor for the risk of adverse outcomes among patients with RA treated with b- or tsDMARDs. This article is protected by copyright. All rights reserved.